The chief of staff of Hungary's Prime Minster, Gergely Gulyas, said on 14 January 2021 that Hungary has reached a deal with China National Pharmaceutical Group Corp ( Sinopharm) to buy COVID-19 vaccines developed by the company, Reuters news agency reported on Thursday.
According to Gulyas, vaccine shipments under the European Union's programme were arriving to Hungary way too slow.
Gulyas was also quoted as telling a government briefing that the second wave of the COVID-19 pandemic has peaked in Hungary and new infections have dropped but restrictions cannot be eased yet.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses